NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
35 hedge funds and large institutions have $31.1M invested in NeuBase Therapeutics, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 0 closing their positions.
1,268% more capital invested
Capital invested by funds: $2.27M → $31.1M (+$28.8M)
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
150% more funds holding
Funds holding: 14 → 35 (+21)
66% less call options, than puts
Call options by funds: $32K | Put options by funds: $93K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$11.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.57M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$2.15M |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$880K |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$853K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$36.9K |
| 2 |
FNBT
FineMark National Bank & Trust
Fort Myers,
Florida
|
-$26.3K |
| 3 |
Goldman Sachs
New York
|
-$10.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $96K | +$89.5K | +17 | +1,700% |
|
|
BIT
27
BlackRock Institutional Trust
San Francisco,
California
| $80K | +$63.2K | +12 | +400% |
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $59K | +$36.9K | +7 | +175% |
|
|
FNBT
29
FineMark National Bank & Trust
Fort Myers,
Florida
| $54K | -$26.3K | -5 | -33% |
|
|
HF
30
Hoxton Financial
Shepherdstown,
West Virginia
| $46K | +$42.1K | +8 | New |
|
|
HCC
31
Hirtle Callaghan & Co
West Conshohocken,
Pennsylvania
| $32K | +$31.6K | +6 | New |
|
32
Citigroup
New York
| $15K | +$15.8K | +3 | New |
|
33
Bank of America
Charlotte,
North Carolina
| $14K | +$15.8K | +3 | New |
|
|
TC
34
TradeLink Capital
Chicago,
Illinois
| $12K | +$10.5K | +2 | New |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| $4K | -$36.9K | -7 | -88% |
|
NBSE Hedge Fund Activity: Q1 2014 in Review
35 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2014, worth a combined $31.1M — up 1,268% from $2.27M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new NBSE positions and 0 closed out — a net gain of 21 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $11.8M. The largest seller was Tower Research Capital (TRC), cutting an estimated $36.9K.
- 35 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2014, up from 14 in Q4 2013.
- Funds reported $31.1M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2014, up 1,268% quarter-over-quarter.
- 21 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2014 and 0 closed out, a net change of +21 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2014 was Millennium Management, an estimated $11.8M added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2014 was Tower Research Capital (TRC), an estimated $36.9K sold.
Based on aggregated 13F filings for Q1 2014.